Levetiracetam Actavis

Levetiracetam, the active ingredient in Levetiracetam Actavis, is an anticonvulsant presented as an oral tablet for oral use. It is prescribed to manage various seizure types, including partial, generalized tonic‑clonic, and myoclonic seizures, in adult and pediatric patients. It is available in several dosage strengths to allow individualized dosing based on clinical assessment.

GNH USA supplies Levetiracetam Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to WHO‑GMP guidelines and provides temperature‑controlled logistics where required.

Levetiracetam is an anticonvulsant used to control seizure activity in epilepsy.

Partial seizures: reduces frequency and severity of focal onset seizures. Generalized tonic‑clonic seizures: helps prevent convulsive episodes in patients with generalized epilepsy. Myoclonic seizures: decreases sudden muscle jerks associated with myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: transient light‑headedness that may affect balance and coordination. - Fatigue: persistent tiredness that can reduce daily activity tolerance. - Headache: mild to moderate pain often relieved with simple analgesics. - Irritability: heightened agitation or mood swings observed in some patients. - Skin reactions: mild rash or itching that usually resolves without treatment.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or Stevens‑Johnson syndrome requiring immediate medical attention. - Mood alterations: depression, anxiety, or suicidal thoughts that should be promptly reported. - Blood disorders: neutropenia, thrombocytopenia, or other hematologic abnormalities observed in laboratory tests.

Before prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

Renal impairment: dose adjustment may be required based on creatinine clearance. History of psychiatric disorders: monitor for mood changes or depressive symptoms. Concomitant CNS depressants: assess additive sedation risk. Pregnancy: potential risks are unknown; use only if benefit outweighs risk. Lactation: unknown safety; consider alternative therapy. Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Levetiracetam can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma concentrations. - Phenobarbital: may decrease levetiracetam levels, reducing seizure control.

Moderate Interactions (Monitor Closely): - Alcohol: additive CNS depression may increase dizziness or sedation. - Other antiepileptic drugs: monitor for synergistic toxicity. - Oral contraceptives: levetiracetam may lower hormone levels, reducing contraceptive effectiveness.